Arete Wealth Advisors LLC Increases Position in Cencora, Inc. (NYSE:COR)

Arete Wealth Advisors LLC boosted its position in Cencora, Inc. (NYSE:COR) by 6.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,565 shares of the company’s stock after purchasing an additional 153 shares during the period. Arete Wealth Advisors LLC’s holdings in Cencora were worth $576,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Hickory Asset Management Inc. purchased a new position in shares of Cencora in the fourth quarter valued at $572,000. Sylvest Advisors LLC acquired a new position in Cencora during the fourth quarter worth about $1,105,000. Insight Wealth Strategies LLC lifted its holdings in shares of Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after purchasing an additional 11,232 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock valued at $1,403,000 after purchasing an additional 1,995 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. grew its position in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after purchasing an additional 2,928 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,675 shares of company stock valued at $8,034,778. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Down 3.5 %

COR opened at $279.29 on Friday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65. The business has a 50-day moving average of $257.28 and a two-hundred day moving average of $242.70. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market capitalization of $54.16 billion, a price-to-earnings ratio of 39.73, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.79%. Cencora’s payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

COR has been the subject of several research reports. Evercore ISI lifted their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their price target on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $280.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.